They found that in vivo blocking Tim-3/galectin-9 interaction on exosomes might sustain the anti-tumoral responses of T cells, thereby improving clinical immunotherapeutic efficacy against NPC [89]. Here, LGALS9 is linked to nasopharyngeal carcinoma.